版本:
中国

BRIEF-U.S. FDA grants accelerated approval to Sarepta Therapeutics' Duchenne Muscular Dystrophy drug

Sept 19 U.S. FDA -

* FDA grants accelerated approval to first drug for Duchenne Muscular Dystrophy

* Approved Sarepta Therapeutics' Exondys 51 (eteplirsen) injection

* Approval of Exondys 51 based on surrogate endpoint of dystrophin increase in skeletal muscle observed in some Exondys 51-treated patients

* Under accelerated approval provisions, FDA is requiring Sarepta Therapeutics to conduct clinical trial to confirm Exondys 51's clinical benefit Source text: (bit.ly/2cCad2V) Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐